Potentially a slightly more drawn out affair than some might...

Potentially a slightly more drawn out affair than some might have hoped regarding FDA and local commercialisation. I would include myself in this category, however I've come to the point of realisation that I am here until both versions of the app are commercialised. I've waited patiently for long enough and short of pulling another rabbit out of the hat ePAT have shown that they are dedicated to the cause.

I often wonder where the share price would be minus the CR and so many options. Probably at least double. The options always loom now the CR is flushed. Sustainable business will soon be a real thing.

At the end of the day I remain very confident in my investment with this company, despite fluctuations in the SP. PainChek appears to be well and truly on track to be a global name. Not just an app, but a clinical tool that is backed by peer reviewed documentation (just a little bit of difference I think).